The Prevalence Of RSV Infections Drives Demand For Abrysvo Vaccine Is Supporting Development Across The Abrysvo Or Arexvy Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Abrysvo Or Arexvy Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The expansion observed during the historical timeframe was primarily driven by several factors, including the existing unmet demand for RSV vaccines, the increasing size of the elderly population, the widespread impact of respiratory infections, the granting of various regulatory approvals, and a heightened public health awareness.

The anticipated growth during the forecast period is due to an expanding elderly population, increasing rates of RSV hospitalization, wider vaccination recommendations, enhanced access through healthcare providers, and a greater focus on preventive healthcare. Significant trends anticipated for this period encompass a growing emphasis on RSV prevention, increased vaccination rates among older adults, the expansion of adult immunization programs, vaccine delivery through hospitals and community settings, and proactive preventive care for high-risk populations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19948&type=smp

Which Core Factors Are Supporting The Expansion Of The Abrysvo Or Arexvy Market?

The abrysvo or arexvy market is anticipated to expand due to the growing occurrence of respiratory syncytial virus (RSV) infections. RSV, a common virus, primarily impacts the respiratory system, often causing mild cold-like symptoms but leading to severe conditions in vulnerable groups such as infants, older adults, and those with compromised immune systems. Its increasing prevalence stems from its highly contagious nature, seasonal patterns, limited widespread immunity, and heightened susceptibility among populations like infants and the elderly. Abrysvo offers a solution by delivering specific vaccines that safeguard high-risk individuals, including older adults and infants, from severe RSV-related ailments. For example, in Oct 2024, the Centers for Disease Control and Prevention reported that during the 2024-25 season, the overall hospitalization rate for RSV reached 3.2 per 100,000 individuals. Consequently, the rising incidence of RSV infections is a key factor boosting the abrysvo or arexvy market.

Abrysvo Or Arexvy Market Driver: Impact Of Rising Healthcare Expenditure On The Growth Of The Market

Which Segment-Based Categories Are Covered In The Abrysvo Or Arexvy Market?

The abrysvo or arexvy market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prevention, Infant Protection

2) By Age Group: Adults (18-59 years), Older Adults (60+ years), Pregnant Individuals (32-36 weeks of gestation)

3) By End User: Healthcare Providers, Pregnant Individuals, High-Risk Adults

Which Trends Are Affecting The Abrysvo Or Arexvy Market Framework?

Leading companies in the abrysvo or arexvy market are concentrating on creating sophisticated products, such as bivalent prefusion F (RSVpreF) vaccines, with the goal of expanding protection, improving safety, and serving high-risk demographics. Bivalent RSVpreF vaccines are formulations crafted to confer immunity against both major RSV subgroups (RSV-A and RSV-B) by targeting the prefusion state of the fusion (F) protein, a critical site for neutralizing antibodies. As an illustration, in October 2024, Pfizer Inc., a US-based pharmaceutical company, secured U.S. Food and Drug Administration (FDA) approval for ABRYSVO (RSV Vaccine), which is a bivalent RSV prefusion F (RSVpreF) vaccine, for preventing lower respiratory tract disease in adults aged 18 to 59 who are at increased risk, thereby extending its approved use to the widest adult population. It continues to be the sole approved RSV vaccine for pregnant individuals between 32 and 36 weeks of gestation to safeguard infants from birth through 6 months.

Who Are The Companies Shaping The Abrysvo Or Arexvy Market Landscape?

Major companies operating in the abrysvo or arexvy market are Pfizer Inc., GlaxoSmithKline plc (GSK)

Access The Complete Abrysvo Or Arexvy Market Report:

https://www.thebusinessresearchcompany.com/report/abrysvo-or-arexvy-global-market-report

Which Region Is The Primary Market For The Abrysvo Or Arexvy Market?

North America was the largest region in the abrysvo or arexvy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the abrysvo or arexvy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Abrysvo Or Arexvy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=19948&type=smp

Browse Through More Reports Similar to the Global Abrysvo Or Arexvy Market 2026, By The Business Research Company

Business Intelligence Bi Vendors Market Report 2026

https://www.thebusinessresearchcompany.com/report/business-intelligence-bi-vendors-global-market-report

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795